Blinatumomab functioned by generating a synapse between cytotoxic T-cells expressing CD3 and ALL cells expressing CD19, thus enabling T-cells to recognize and lyse malignant B-cells [12]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.